Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dialysis easier through Thoratec vascular graft:

This article was originally published in Clinica

Executive Summary

Thoratec has asked the FDA for an investigational device exemption to allow it to begin trials of its vascular access graft, a synthetic graft providing access to the bloodstream of dialysis patients. Data from a Japanese study shows the VAG is 91% open to blood flow after 12 months - much higher than competing grafts, says the company. It also permits start of dialysis within three days compared to two weeks.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts